Chafekar Deodatta
Dr V N Pawar Medical College, Director Supreme Kidney Care, Nashik 422005, Mahārāshtra, India.
World J Nephrol. 2025 Mar 25;14(1):101515. doi: 10.5527/wjn.v14.i1.101515.
Chronic kidney disease (CKD), which represents a significant global health concern, is characterized by a gradual decline in kidney function, leading to complications such as electrolyte imbalance, cardiovascular disease, and immune dysfunction. Standard CKD management includes dietary modifications, ketoanalogues supplementation, blood pressure and blood glucose control, hydration maintenance, and treatment of the underlying causes. Emerging evidence has indicated a significant role of the gut microbiota in CKD, and that dysbiosis of the gut microbiota contributes to the progression of CKD towards end-stage renal disease. Probiotics and prebiotics have recently garnered attention owing to their potential to enhance gastrointestinal health and well-being by restoring the balance of the gut microbiota. Specific probiotic strains, including and , promote beneficial bacterial growth, suppress harmful bacteria, and exert anti-inflammatory, antihypertensive, and antidiabetic effects. The combination of , , , and has demonstrated potential as a therapeutic formulation for CKD management in various studies, highlighting its promise in treating CKD; however, supporting evidence remains limited, making it crucial to conduct further investigations to determine the specific effects of different probiotic formulations on outcomes in patients with CKD.
慢性肾脏病（CKD）是一个重大的全球健康问题，其特征是肾功能逐渐下降，导致诸如电解质失衡、心血管疾病和免疫功能障碍等并发症。CKD的标准管理包括饮食调整、补充酮类似物、控制血压和血糖、维持水合作用以及治疗潜在病因。新出现的证据表明肠道微生物群在CKD中起重要作用，并且肠道微生物群失调会促使CKD进展至终末期肾病。益生菌和益生元最近因其通过恢复肠道微生物群平衡来增强胃肠道健康和福祉的潜力而受到关注。特定的益生菌菌株，包括[具体菌株1]和[具体菌株2]，可促进有益细菌生长、抑制有害细菌，并发挥抗炎、降压和抗糖尿病作用。在各项研究中，[具体菌株1]、[具体菌株2]、[具体菌株3]和[具体菌株4]的组合已显示出作为CKD管理治疗制剂的潜力，突出了其在治疗CKD方面的前景；然而，支持证据仍然有限，因此开展进一步研究以确定不同益生菌制剂对CKD患者结局的具体影响至关重要。
